Chemomab Therapeutics Ltd - ADR
CMMB
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.68M
Close$
$1.19
56.6% downside
Current Fair Value
56.6% downsideOvervalued by 56.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.68 Million |
|---|---|
| Enterprise Value | $10.68 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.42 |
| Beta | 0.66 |
| Outstanding Shares | 8,003,049 |
Return
| Return on Equity | -87.47% |
|---|---|
| Return on Assets | -74.21% |
| Return on Invested Capital | -91.86% |
Valuation & Multiples
| P/E Ratio | -2.65 |
|---|---|
| PEG | -37.57 |
| Price to Sales | - |
| Price to Book Ratio | 2.73 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.34 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.41%▼ 0.29% |
|---|---|
| Total Invested | $551,949▼ 8.94% |
| Investors Holding | 15▲ 1.00% |
ESG Score
No data
About Chemomab Therapeutics Ltd
2,020 employeesChemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in pr...